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Sonnenberg et al1 reported striking
variations in the ethnic distributions of
gastroesophageal reflux disease (GERD)
and Barrett esophagus (BE). Both diseases
were associated with a lower prevalence of
Helicobacter pylori infection (Hp-I) than
the control population, though its preva-
lence in GERD and BE was higher in
male than female patients, thereby run-
ning contrary to a simple consideration of
an inverse relationship between Hp-I and
these diseases.1
In this regard, we recently suggested
that epidemiological studies regarding
Hp-I, GERD and BE-related esophageal
adenocarcinoma (EAC) underestimated
potential co-factors of EAC development.2
Furthermore, large-scale studies concluded
against the protective role of Hp to
GERD.2 The current worldwide Hp-I
prevalence is about 58% (varied from
39.9% to 84.2%)3; its current prevalence in
Asia is 66.6%. In contrast, the current
global prevalence of GERD varies from
2.5% to 51.2%; its range in Asia is 33%
compared with 28% of the western
countries.3 This means that the conven-
tional claim that declining Hp prevalence
has led to a rise in GERD and its com-
plications BE and EAC3,4 needs to be
carefully studied. For instance, a large-
scale study (∼21,000 cases) reported that
the decline in Hp-I parallels the reduction
in peptic ulcer prevalence, and that the rise
in GERD and/or reappearance of GERD
following Hp therapy is rare2; contrary to
expectations, patients hospitalized with
duodenal ulcers (∼61,500 cases), obviously
attributed to Hp-I, had a 70% increased
risk of EAC5; Malaysians, who for a long
time have had a low prevalence of Hp-I,
also show a low incidence of GERD, BE
and distal esophageal cancers, signifying
that Hp-I is not protective against these
pathologies and its absence may be
beneficial6; in a predominantly Caucasian
population with a high prevalence of
Hp gastritis, Hp-I was not inversely con-
nected with BE (neither presence of erosive
esophagitis, length of BE nor dysplasia
was associated with the presence ofHp-I)7;
2 additional studies showed that Hp erad-
ication leads to better control of GERD
symptoms and improves esophagitis.8,9
Moreover, other authors, previous sup-
porters of the hypothesis that Hp “pro-
tects” against GERD, relented, claiming
that Hp therapy does not cause or protect
against GERD, and recommending Hp
eradication in GERD.10 Such data further
potentiate the consideration that Hp is
not “protective” against anything, includ-
ing GERD11 and its complications BE
and EAC.
Likewise, the hypothesis that incr-
eased acidity, afterHp-I eradication, could
trigger GERD-BE-EAC sequence war-
rants careful reconsideration. Contrariwise,
transient lower esophageal sphincter (LES)
relaxations consist the substantial compo-
nent of esophageal injury3 and Hp-I dis-
ables normal LES, probably by nitric
oxide intermittent overproduction and
nonselective relaxation of smooth muscles.
In addition, Hp-I influences the gastro-
intestinal microbiota composition includ-
ing the presence of gastric species such as
Campylobacter; Hp-I induced atrophy
impairs the chemical defense of stomach,
thus promoting the gastric microbiota
dysbiosis which might contribute to BE-
EAC sequence as etc implied by the high
concentrations of Campylobacter species in
BE biofilm and the predominance of
gram-negative bacteria.3 Moreover, Hp
could directly hurt the esophagus and
induce prostaglandins (PGs) over-
production that relax LES.2 At molecular
level, Hp-I induces, oncogenic gastrin and
other molecular alterations which contrib-
ute to BE malignant progression.2,3 Spe-
cifically, Hp-I induced oncogenic gastrin,
which, concerning its essential role in
oncogenic progression in BE, stimulates
proliferation via Janus Kinase (JAK) 2
and Akt-dependent nuclear factor-kappa
B (NF-κB) activation in Barrett’s EAC
cells, exhibits an anti-apoptotic effect via
Bcl-2 protein and survivin upregulations,
and provokes the mitogenic and carcino-
genic cyclooxygenase (COX)-2 expression.
Moreover, Hp activates the mentioned
NF-κB, a transcription regulator of
inflammatory genes, including COX-2 that
regulates gastrointestinal malignant cell
growth and proliferation. PGs originated
from upregulated COX-2 are involved in
BEmalignant progression, by perpetuating
chronic inflammation and the mitogenic
and anti-apoptotic actions of PGs are
mediated via activation of many afore-
mentioned signaling pathways including
NF-κB, Src, JAK2/STAT3, ERK,MAPK
and PI3K/Akt kinases. In addition, Hp-
I could trigger specific molecular alter-
ations (genetic instability, E-cadherin
methylation, monoclonal antibody Das-
1) connected with BE pathophysiology,
and stimulated Ki-67 expression pre-
dicting neoplasting progression in BE.3
Furthermore, Hp-related metabolic syn-
drome appears to contribute to the
pathophysiology of GERD-BE-EAC
sequence,12,13 and thus further research
is needed to clarify this topic.
A final dilemma arises: Which
cancer do we prefer to deal with, gastric
cancer or EAC? The plethora of agents
contributing to EAC does not allow to
simplify its pathogenesis and thus the
Hp-I positive association with gastric
cancer, duodenal cancer, and colorectal
cancer12,14 but negative association
with EAC appears inconsistent, thereby
warranting further investigation.
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